{"id":8566,"date":"2026-10-26T08:36:12","date_gmt":"2026-10-26T03:06:12","guid":{"rendered":"https:\/\/www.wittytrades.com\/market-news\/lupin-share-price-today-2026-10-26\/"},"modified":"2026-10-26T17:23:56","modified_gmt":"2026-10-26T11:53:56","slug":"lupin-share-price-today-2026-10-26","status":"publish","type":"post","link":"https:\/\/www.wittytrades.com\/market-news\/lupin-share-price-today-2026-10-26\/","title":{"rendered":"LUPIN Share Price Today: Why LUPIN Is Rising 1.61% | 26 October 2026"},"content":{"rendered":"<style id=\"wt-article-style-v4\">:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) { color:#30475c; font-size:16px; line-height:1.65; min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) *, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) *::before, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) *::after { box-sizing:border-box; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-copy { font-size:16px !important; line-height:1.65 !important; margin:0 0 12px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-prose .wt-copy { margin-bottom:15px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-market-date { font-size:13px !important; line-height:1.55; color:#566b80; background:#f2f6f9; border:1px solid #dde6ec; border-left:4px solid #2e7db2; border-radius:6px; padding:8px 11px; margin:0 0 12px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip { display:grid; grid-template-columns:repeat(6,minmax(0,1fr)); gap:7px; margin:8px 0 16px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div { padding:10px !important; min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div > div:first-child { font-size:11px !important; line-height:1.45; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div > div:last-child { font-size:14px !important; line-height:1.5; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card { padding:14px 16px; min-width:0; overflow-wrap:anywhere; margin:14px 0 18px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-title { font-size:16px; font-weight:800; line-height:1.45; color:#17324d; margin-bottom:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-date { font-size:13px; line-height:1.5; color:#566b80; margin-bottom:9px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-body { font-size:16px; line-height:1.6; color:#34495d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-body .wt-copy:last-child { margin-bottom:0 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid { display:grid; grid-template-columns:repeat(2,minmax(0,1fr)); gap:12px; margin:12px 0 18px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid > .wt-card { margin:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid > :only-child { grid-column:1 \/ -1; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-metrics { grid-template-columns:repeat(3,minmax(0,1fr)); margin:10px 0 12px; gap:10px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-metric { background:#fff; border:1px solid #e1e8ef; border-radius:8px; padding:10px 12px; min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-label { display:block; font-size:12px; font-weight:700; color:#566b80; line-height:1.5; margin-bottom:3px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-value { font-size:18px; font-weight:800; line-height:1.45; color:#17324d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-note { display:block; font-size:13px; color:#566b80; line-height:1.55; margin-top:4px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-source-note { margin:9px 0 4px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-source { display:inline-block; font-size:13px; line-height:1.5; margin-top:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row { display:grid; grid-template-columns:2fr 1fr 1.2fr 1.2fr; gap:14px; padding:12px 0; border-bottom:1px solid #c9dbef; align-items:start; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row:last-of-type { border-bottom:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row strong { font-size:15px; line-height:1.5; display:block; color:#17324d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row > div { min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds { grid-template-columns:repeat(3,minmax(0,1fr)); margin:12px 0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card { padding:12px; background:#fff !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-title { font-size:14px; font-weight:700; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-body { font-size:14px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-brokerage { grid-template-columns:1fr; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-broker-facts { display:flex; flex-wrap:wrap; gap:14px 28px; margin:7px 0 12px; padding-bottom:10px; border-bottom:1px solid #cbd8ea; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-broker-facts strong { font-size:16px; color:#17324d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-list { font-size:16px !important; line-height:1.65; margin:0 0 12px; padding-left:20px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-list li { margin-bottom:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-takeaways .wt-card { background:#f7fbff !important; border-color:#cfe1f2 !important; border-left-color:#2e7db2 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-takeaways .wt-card-title { color:#1f4d70; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-takeaways .wt-list { margin-bottom:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-likely-reason .wt-card { background:#f5fbfd !important; border-color:#c9d9e7 !important; border-left:5px solid #1f7b92 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-likely-reason .wt-card-title { color:#174c5d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-likely-reason .wt-card-body > strong { display:block; margin-bottom:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta { padding:18px 19px; margin:22px 0; border-radius:13px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-title { font-size:19px; font-weight:800; line-height:1.4; margin-bottom:7px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-yellow { background:linear-gradient(135deg,#ffe873,#ffd64a); border:1px solid #e3b600; box-shadow:0 8px 18px rgba(59,48,0,.09); }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-yellow .wt-cta-title { color:#10233f !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-yellow .wt-cta-copy { color:#27364b !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark { background:#10233f; box-shadow:0 9px 22px rgba(16,35,63,.18); }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark .wt-cta-title { color:#fff !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark .wt-cta-copy { color:#dce6f1 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-copy { font-size:16px !important; line-height:1.6; margin:0 0 12px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-button { display:inline-block; background:#10233f; color:#fff !important; padding:10px 17px; border-radius:7px; text-decoration:none !important; font-size:15px; font-weight:800; line-height:1.5; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark .wt-cta-button { background:#ffe36e; color:#10233f !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-faq h3 { color:#173b58 !important; font-size:17px !important; line-height:1.45; margin:18px 0 6px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) > p:last-child { font-size:13px; line-height:1.55; color:#606b78; border-top:1px solid #e1e7ef; padding-top:13px; margin-top:16px; }\n@media (max-width:960px) {\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip { grid-template-columns:repeat(3,minmax(0,1fr)); }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row { grid-template-columns:1.7fr 1fr 1.2fr 1.2fr; gap:10px; }\n}\n@media (max-width:650px) {\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid { grid-template-columns:1fr; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-metrics { grid-template-columns:repeat(2,minmax(0,1fr)); }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card { padding:14px; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row { grid-template-columns:repeat(2,minmax(0,1fr)); gap:10px 14px; padding:12px 0; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-person, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row > div:last-child { grid-column:1 \/ -1; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta { padding:17px 15px; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-title { font-size:18px; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div { padding:9px !important; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-title, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-body { font-size:15px; }\n}\n@media (max-width:420px) {\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip { grid-template-columns:repeat(2,minmax(0,1fr)); }\n}<\/p>\n<p>:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div {border:1px solid #dde6ee;border-radius:8px;background:#f9fbfd;}\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div > div:last-child {font-weight:800;color:#17324d;}\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) h2 {font-size:24px !important;line-height:1.35 !important;margin:28px 0 14px !important;color:#173b58;}\n<\/style>\n<div class=\"wt-article-v4\" data-witty-phase=\"live\" data-article-version=\"4\">\n<p class=\"wt-market-date\"><strong>NSE: LUPIN<\/strong> \u00b7 26 October 2026<\/p>\n<div class=\"wt-price-strip\">\n<div>\n<div>Price<\/div>\n<div>\u20b91,959.90<\/div>\n<\/div>\n<div>\n<div>Change<\/div>\n<div>+1.61%<\/div>\n<\/div>\n<div>\n<div>High \/ Low<\/div>\n<div>\u20b91,959.90 \/ \u20b91,918.40<\/div>\n<\/div>\n<div>\n<div>Prev. Close<\/div>\n<div>\u20b91,928.90<\/div>\n<\/div>\n<div>\n<div>Volume<\/div>\n<div>4.38 lakh<\/div>\n<\/div>\n<div>\n<div>Price as of<\/div>\n<div>26 October 2026 \u00b7 03:25 PM IST<\/div>\n<\/div>\n<\/div>\n<div class=\"wt-takeaways\">\n<div class=\"wt-card\" data-card=\"research\" style=\"background:#f4f8fd;border:1px solid #cbd8ea;border-left:4px solid #466fa5;border-radius:10px\">\n<div class=\"wt-card-title\">Key Takeaways<\/div>\n<div class=\"wt-card-body\">\n<ul class=\"wt-list\">\n<li>Lupin Limited shares moved higher during the trading session on October 26, 2026, gaining 1.61% to close at \u20b91959.90 compared to the previous close of \u20b91928.90. The stock opened at \u20b91924.10, touched an intraday high of \u20b91959.90, and a low of \u20b91918.40.<\/li>\n<li>Lupin Limited informed stock exchanges that the U.S. FDA concluded an inspection at its manufacturing facility located in Goa, India. The inspection took place from October 19, 2026, to October 23, 2026, and concluded with the issuance of a Form-483 containing one observation. The company stated it will address the observation and respond to the regulator within the stipulated timeframe.<\/li>\n<li>Trading volume was 0.64 times the 20-day average daily volume.<\/li>\n<\/ul>\n<\/div>\n<\/div>\n<\/div>\n<h2>Why is LUPIN share price rising on 26 October 2026?<\/h2>\n<div class=\"wt-prose\">\n<p class=\"wt-copy\">Lupin Limited shares moved higher during the trading session on October 26, 2026, gaining 1.61% to close at \u20b91959.90 compared to the previous close of \u20b91928.90. The stock opened at \u20b91924.10, touched an intraday high of \u20b91959.90, and a low of \u20b91918.40.<\/p>\n<p class=\"wt-copy\">The broader market and sectoral trend provided supportive backdrop for the stock. The benchmark Nifty rose by 0.68%, while the Nifty Pharma sector index advanced by 1.76%, reflecting strong buying interest across pharmaceutical counters. Over the short term, Lupin&#x27;s returns showed mild consolidation with a 5-day return of -0.09% and a 20-day return of -6.70%.<\/p>\n<p class=\"wt-copy\">Company-specific news flow includes the U.S. FDA concluding an inspection at Lupin&#x27;s manufacturing facility in Goa, India, which closed with a Form-483 containing a single observation. Additionally, the company recently announced the appointment of Brian Savage as President and Chief Legal Officer, strengthening its global legal and compliance leadership team. While these developments provide ongoing corporate context, the session&#x27;s price action aligns closely with broader sectoral momentum.<\/p>\n<p class=\"wt-copy\">4.38 lakh shares traded by 26 October 2026 \u00b7 03:25 PM IST. This compares with a 20-day average daily volume of 6.88 lakh shares (0.64 times). The five-day average daily volume was 6.79 lakh shares. Separately, the NSE report for 23 October 2026 showed 3.91 lakh shares delivered, representing 55.72% of that day\u2019s traded volume. The same report recorded 43,768 trades.<\/p>\n<\/div>\n<div class=\"wt-likely-reason\">\n<div class=\"wt-card\" data-card=\"research\" style=\"background:#f4f8fd;border:1px solid #cbd8ea;border-left:4px solid #466fa5;border-radius:10px\">\n<div class=\"wt-card-title\">Likely Reason<\/div>\n<div class=\"wt-card-body\"><strong>sectoral tailwinds and positive pharma momentum<\/strong><\/p>\n<p class=\"wt-copy\">Lupin&#x27;s 1.61% gain aligns with strong buying in the pharmaceutical sector, where the Nifty Pharma index advanced 1.76%. Recent operational updates, including the Goa facility inspection closure and leadership appointments, provided a supportive backdrop, though trading volumes remained below the 20-day average.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<aside class=\"wt-cta wt-cta-yellow\">\n<div class=\"wt-cta-title\">Research the Market \u2014 Not Just the Headline<\/div>\n<p class=\"wt-cta-copy\">Explore WittyTrades research across market segments.<\/p>\n<p><a class=\"wt-cta-button\" href=\"https:\/\/www.wittytrades.com\/Segments.html\">Explore WittyTrades Research \u2192<\/a><\/aside>\n<h2>Latest Company Developments<\/h2>\n<div class=\"wt-grid wt-grid-news\">\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">US FDA Inspection at Goa Facility<\/div>\n<div class=\"wt-card-date\">24 October 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">Lupin Limited informed stock exchanges that the U.S. FDA concluded an inspection at its manufacturing facility located in Goa, India. The inspection took place from October 19, 2026, to October 23, 2026, and concluded with the issuance of a Form-483 containing one observation. The company stated it will address the observation and respond to the regulator within the stipulated timeframe.<\/p>\n<p class=\"wt-copy\">Resolving regulatory observations efficiently is vital for maintaining uninterrupted export operations and sustaining growth momentum in key regulated markets like the U.S.<\/p>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/Lupin2_24102026141953_SEintimation_Goa_24102026.pdf\" rel=\"noopener\">Original source \u2192<\/a><\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Appointment of Brian Savage as Chief Legal Officer<\/div>\n<div class=\"wt-card-date\">23 October 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">Lupin announced the appointment of Brian Savage as President and Chief Legal Officer, effective October 22, 2026. In this role, Savage will lead the company&#x27;s global Legal, Compliance, and Intellectual Property Management Group functions, operating from New Jersey. He brings extensive industry experience, having previously served in senior legal leadership roles at Teva Pharmaceuticals.<\/p>\n<p class=\"wt-copy\">Strengthening executive leadership in legal and compliance helps navigate complex regulatory landscapes and supports long-term strategic governance.<\/p>\n<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">U.S. FDA Approval for Phytonadione Injectable Emulsion<\/div>\n<div class=\"wt-card-date\">9 October 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">Lupin received final approval from the U.S. FDA for its Phytonadione Injectable Emulsion, USP, expanding its specialty product portfolio in the United States. This regulatory clearance adds to the company&#x27;s pipeline execution and strengthens its commercial offerings in North America. The product will be manufactured at Lupin&#x27;s dedicated facility.<\/p>\n<p class=\"wt-copy\">New product approvals in regulated markets drive portfolio diversification and contribute to top-line growth in the core North American business.<\/p>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/Lupin2_08102026205937_SELetterPressRelease.pdf\" rel=\"noopener\">Original source \u2192<\/a><\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">General Updates<\/div>\n<div class=\"wt-card-date\">24 October 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">Lupin Limited has informed the Exchange that U.S. FDA has concluded an inspection at our manufacturing facility located in Goa, India.<\/p>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/Lupin2_24102026141953_SEintimation_Goa_24102026.pdf\" rel=\"noopener\">Original source \u2192<\/a><\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Business update<\/div>\n<div class=\"wt-card-date\">9 October 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">a press release dated October 08, 2026, titled &quot;Lupin Receives U.S. FDA Approval for Phytonadione Injectable Emulsion, USP&quot;.<\/p>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/Lupin2_08102026205937_SELetterPressRelease.pdf\" rel=\"noopener\">Original source \u2192<\/a><\/div>\n<\/div>\n<\/div>\n<h2>Ownership &amp; Transaction Activity<\/h2>\n<div class=\"wt-grid wt-grid-ownership\">\n<div class=\"wt-card\" data-card=\"ownership\" style=\"background:#fff8e8;border:1px solid #ecd39e;border-left:4px solid #cc922c;border-radius:10px\">\n<div class=\"wt-card-title\">Shareholding<\/div>\n<div class=\"wt-card-date\">As of 30 September 2026<\/div>\n<div class=\"wt-card-body\">\n<div class=\"wt-grid wt-grid-metrics\">\n<div class=\"wt-metric\">\n<div class=\"wt-label\">Promoter holding<\/div>\n<div class=\"wt-value\">46.84%<\/div>\n<div class=\"wt-note\">46.85% on 30 June 2026<\/div>\n<\/div>\n<div class=\"wt-metric\">\n<div class=\"wt-label\">FII\/FPI<\/div>\n<div class=\"wt-value\">23.28%<\/div>\n<div class=\"wt-note\">22.42% on 30 June 2026<\/div>\n<\/div>\n<div class=\"wt-metric\">\n<div class=\"wt-label\">Institutional holding<\/div>\n<div class=\"wt-value\">47.06%<\/div>\n<div class=\"wt-note\">47.07% on 30 June 2026<\/div>\n<\/div>\n<\/div>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/xbrl\/SHP_1741171_19102026114146_WEB.xml\" rel=\"noopener\">NSE shareholding filing \u2192<\/a><\/div>\n<\/div>\n<\/div>\n<h2>Mutual Fund Holdings<\/h2>\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">Mutual-fund ownership<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">Mutual funds held 14.58% on 30 September 2026. This compares with 14.84% on 30 June 2026, a change of -0.26 percentage points.<\/p>\n<p class=\"wt-copy\">The filing reported 43 MF\/UTI holders.<\/p>\n<div class=\"wt-grid wt-grid-funds\">\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">HDFC Mutual Fund-HDFC Arbitrage Fund<\/div>\n<div class=\"wt-card-date\">30 September 2026<\/div>\n<div class=\"wt-card-body\">2.14 crore shares \u00b7 4.68%<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">Nippon Life India Trustee Ltd- A\/C Nippon India Growth Mid Cap Fund<\/div>\n<div class=\"wt-card-date\">30 September 2026<\/div>\n<div class=\"wt-card-body\">1.07 crore shares \u00b7 2.33%<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">Mirae Asset BSE LARGEMID (60:40) Stable Dividend 50 ETF<\/div>\n<div class=\"wt-card-date\">30 September 2026<\/div>\n<div class=\"wt-card-body\">85.86 lakh shares \u00b7 1.88%<\/div>\n<\/div>\n<\/div>\n<div class=\"wt-note wt-source-note\">These are quarterly holdings, rather than purchases or sales on the article date.<\/div>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/xbrl\/SHP_1741171_19102026114146_WEB.xml\" rel=\"noopener\">NSE shareholding filing \u2192<\/a><\/div>\n<\/div>\n<h2>Historical Bulk \/ Block Deals<\/h2>\n<div class=\"wt-grid wt-grid-cards\">\n<div class=\"wt-card\" data-card=\"deals\" style=\"background:#fff8f2;border:1px solid #ead4c0;border-left:4px solid #b17640;border-radius:10px\">\n<div class=\"wt-card-title\">Block<\/div>\n<div class=\"wt-card-date\">27 August 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">Price Action | Lupin shares slip as Citi downgrades to sell; ICICI Pru AMC slips 3% on block deal. Price Action | Lupin shares slip as Citi downgrades to sell; ICICI Pru AMC slips 3% on block deal Moneycontrol.com<\/p>\n<div class=\"wt-note wt-source-note\">Moneycontrol.com<\/div>\n<\/div>\n<\/div>\n<\/div>\n<h2>What to Watch Next<\/h2>\n<ul class=\"wt-list\">\n<li>Upcoming financial results for the quarter and half year ended September 30, 2026<\/li>\n<li>Company response and remediation regarding the single Goa facility U.S. FDA observation<\/li>\n<li>Execution of recent U.S. FDA approvals and new product launches<\/li>\n<li>Delivery volume trends and cash market participation relative to the 20-day average volume<\/li>\n<\/ul>\n<h2>Other Dated Coverage<\/h2>\n<ul class=\"wt-list\">\n<li><a href=\"https:\/\/www.wittytrades.com\/market-news\/lupin-share-price-today-2026-10-23\/\">LUPIN Share Price Today: Why LUPIN Is Falling 0.01% | 23 October 2026 \u2014 23 October 2026<\/a><\/li>\n<li><a href=\"https:\/\/www.wittytrades.com\/market-news\/lupin-share-price-today-2026-10-22\/\">LUPIN Share Price Today: Why LUPIN Is Falling 2.14% | 22 October 2026 \u2014 22 October 2026<\/a><\/li>\n<li><a href=\"https:\/\/www.wittytrades.com\/market-news\/lupin-share-price-today-2026-10-16\/\">Lupin in Focus Today Following Independent FY26 ESG Rating Assignment | 16 October 2026 \u2014 16 October 2026<\/a><\/li>\n<\/ul>\n<p><a href=\"https:\/\/www.wittytrades.com\/market-news\/tag\/lupin\/\">More LUPIN news and dated analysis \u2192<\/a><\/p>\n<aside class=\"wt-cta wt-cta-dark\">\n<div class=\"wt-cta-title\">Looking for Research-Backed Market Opportunities?<\/div>\n<p class=\"wt-cta-copy\">Explore WittyTrades research across market segments.<\/p>\n<p><a class=\"wt-cta-button\" href=\"https:\/\/www.wittytrades.com\/Segments.html\">Explore WittyTrades Research \u2192<\/a><\/aside>\n<h2>Frequently Asked Questions<\/h2>\n<div class=\"wt-faq\">\n<h3>What is the latest LUPIN company news?<\/h3>\n<p class=\"wt-copy\">Lupin Limited informed stock exchanges that the U.S. FDA concluded an inspection at its manufacturing facility located in Goa, India. The inspection took place from October 19, 2026, to October 23, 2026, and concluded with the issuance of a Form-483 containing one observation. The company stated it will address the observation and respond to the regulator within the stipulated timeframe.<\/p>\n<h3>How strong was LUPIN\u2019s trading volume?<\/h3>\n<p class=\"wt-copy\">4.38 lakh shares traded, 0.64 times the 20-day average daily volume. The price and volume data are dated 26 October 2026 \u00b7 03:25 PM IST.<\/p>\n<h3>Do the mutual-fund figures show buying today?<\/h3>\n<p class=\"wt-copy\">They show holdings on 30 September 2026. Quarterly holdings do not identify purchases made on the article date.<\/p>\n<\/div>\n<p><strong>Research &amp; analysis:<\/strong> <a href=\"https:\/\/www.wittytrades.com\/About_Us.html\">WittyTrades Research Desk<\/a><br \/><strong>Reviewed by:<\/strong> <a href=\"https:\/\/www.wittytrades.com\/About_Us.html\">Mohanish Sanghavi \u2014 SEBI Registered Research Analyst<\/a><\/p>\n<p>Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.<\/p>\n<\/div>\n<p><script type=\"application\/ld+json\">{\"@context\": \"https:\/\/schema.org\", \"@graph\": [{\"@type\": \"WebSite\", \"@id\": \"https:\/\/www.wittytrades.com\/#website\", \"url\": \"https:\/\/www.wittytrades.com\/\", \"name\": \"WittyTrades\", \"publisher\": {\"@id\": \"https:\/\/www.wittytrades.com\/#organization\"}, \"inLanguage\": \"en-IN\"}, {\"@type\": \"Organization\", \"@id\": \"https:\/\/www.wittytrades.com\/#organization\", \"name\": \"WittyTrades\", \"alternateName\": \"Witty Networks\", \"url\": \"https:\/\/www.wittytrades.com\/\", \"telephone\": \"+91-22-48972020\", \"identifier\": [{\"@type\": \"PropertyValue\", \"propertyID\": \"SEBI Research Analyst Registration\", \"value\": \"INH000008172\"}, {\"@type\": \"PropertyValue\", \"propertyID\": \"BSE Research Analyst Code\", \"value\": \"5430\"}]}, {\"@type\": \"Organization\", \"@id\": \"https:\/\/www.wittytrades.com\/#research-desk\", \"name\": \"WittyTrades Research Desk\", \"url\": \"https:\/\/www.wittytrades.com\/About_Us.html\", \"parentOrganization\": {\"@id\": \"https:\/\/www.wittytrades.com\/#organization\"}}, {\"@type\": \"Person\", \"@id\": \"https:\/\/www.wittytrades.com\/About_Us.html#mohanish-sanghavi\", \"name\": \"Mohanish Sanghavi\", \"jobTitle\": \"SEBI Registered Research Analyst\", \"url\": \"https:\/\/www.wittytrades.com\/About_Us.html\", \"worksFor\": {\"@id\": \"https:\/\/www.wittytrades.com\/#organization\"}, \"identifier\": {\"@type\": \"PropertyValue\", \"propertyID\": \"SEBI Research Analyst Registration\", \"value\": \"INH000008172\"}}, {\"@type\": \"NewsArticle\", \"@id\": \"https:\/\/www.wittytrades.com\/market-news\/lupin-share-price-today-2026-10-26\/#article\", \"mainEntityOfPage\": {\"@type\": \"WebPage\", \"@id\": \"https:\/\/www.wittytrades.com\/market-news\/lupin-share-price-today-2026-10-26\/\"}, \"headline\": \"LUPIN Share Price Today: Why LUPIN Is Rising 1.61% | 26 October 2026\", \"description\": \"LUPIN share price rose 1.61% to \u20b91,959.90 today. See why LUPIN is rising, volume context, company developments and what to watch next.\", \"datePublished\": \"2026-10-26T03:06:12Z\", \"dateModified\": \"2026-10-26T17:23:48.707250+05:30\", \"author\": {\"@id\": \"https:\/\/www.wittytrades.com\/#research-desk\"}, \"reviewedBy\": {\"@id\": \"https:\/\/www.wittytrades.com\/About_Us.html#mohanish-sanghavi\"}, \"publisher\": {\"@id\": \"https:\/\/www.wittytrades.com\/#organization\"}, \"isPartOf\": {\"@id\": \"https:\/\/www.wittytrades.com\/#website\"}, \"about\": {\"@type\": \"Thing\", \"name\": \"LUPIN\", \"identifier\": {\"@type\": \"PropertyValue\", \"propertyID\": \"NSE Symbol\", \"value\": \"LUPIN\"}}, \"inLanguage\": \"en-IN\", \"isAccessibleForFree\": true, \"image\": [\"https:\/\/www.wittytrades.com\/market-news\/wp-content\/uploads\/2026\/10\/lupin-company-news-2026-10-26.jpg\"]}]}<\/script><!-- wt-article-record:{\"news_events\":[{\"title\":\"General Updates\",\"summary\":\"Lupin Limited has informed the Exchange that U.S. FDA has concluded an inspection at our manufacturing facility located in Goa, India.\",\"source\":\"NSE\",\"published\":\"24-Oct-2026 14:26:03\",\"source_type\":\"official filing\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/Lupin2_24102026141953_SEintimation_Goa_24102026.pdf\",\"disclosure_text\":\"LUPIN LIMITED Registered Office: 3rd Floor, Kalpataru Inspire, Off W. E. Highway, Santacruz (East), Mumbai - 400 055 India. Tel: (91-22) 6640 2323. Corporate Identity Number: L24100MH1983PLC029442 info@lupin.com | www.lupin.com October 24, 2026 National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051 BSE Limited P. J. Towers, Dalal Street, Mumbai Samachar Marg, Mumbai - 400 001 Symbol: LUPIN Scrip Code: Equity - 500257 Subject: Disclosure pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (\u2018SEBI Listing Regulations\u2019) Dear Sir\/Madam, We would like to inform you that the U.S. FDA has concluded an inspection at our manufacturing facility located in Goa, India. The inspection was conducted from October 19, 2026, to October 23, 2026, and closed with the issuance of a Form-483 with one observation. We will address the observation and respond to the U.S. FDA within the stipulated timeframe. We are committed to be compliant with CGMP standards across all our facilities. This may kindly be considered as a disclosure pursuant to Regulation 30 of the SEBI Listing Regulations. Thanking you, For LUPIN LIMITED AMIT KUMAR GUPTA COMPANY SECRETARY & COMPLIANCE OFFICER (ACS -15754)\"},{\"summary\":\"a press release dated October 08, 2026, titled \\\"Lupin Receives U.S. FDA Approval for Phytonadione Injectable Emulsion, USP\\\".\",\"category\":\"Press Release\",\"date\":\"08-Oct-2026 21:00:15\",\"source\":\"NSE filing\",\"industry\":\"Pharmaceuticals\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/Lupin2_08102026205937_SELetterPressRelease.pdf\",\"headline\":\"Business update\",\"impact\":\"This is a substantive business update. Its relevance depends on whether it changes revenue growth, margins, capacity, competitive positioning or execution visibility.\",\"importance_score\":4,\"completeness_score\":3},{\"summary\":\"a press release dated October 06, 2026, titled \\\"Lupin Launches Formoflo-G\u00ae MDI, World s First Fixed-dose Triple Combination Drug for COPD Management\\\".\",\"category\":\"Press Release\",\"date\":\"06-Oct-2026 09:38:12\",\"source\":\"NSE filing\",\"industry\":\"Pharmaceuticals\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/Lupin2_06102026093541_SELetterpressrelease.pdf\",\"headline\":\"Business update\",\"impact\":\"This is a substantive business update. Its relevance depends on whether it changes revenue growth, margins, capacity, competitive positioning or execution visibility.\",\"importance_score\":4,\"completeness_score\":4},{\"summary\":\"a press release dated September 28, 2026, titled \\\"Lupin Receives Tentative Approval from U.S. FDA for Novel Apixaban Oral Suspension\\\".\",\"category\":\"Press Release\",\"date\":\"28-Sep-2026 09:13:36\",\"source\":\"NSE filing\",\"industry\":\"Pharmaceuticals\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/Lupin2_28092026091311_SELetterPressRelease.pdf\",\"headline\":\"Business update\",\"impact\":\"This is a substantive business update. Its relevance depends on whether it changes revenue growth, margins, capacity, competitive positioning or execution visibility.\",\"importance_score\":4,\"completeness_score\":3},{\"summary\":\"a press release dated September 04, 2026, titled \\\"Lupin Receives U.S. FDA Approval for Modafinil Tablets, USP\\\".\",\"category\":\"Press Release\",\"date\":\"04-Sep-2026 17:38:35\",\"source\":\"NSE filing\",\"industry\":\"Pharmaceuticals\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/Lupin2_04092026173742_SELetterPressRelease.pdf\",\"headline\":\"Business update\",\"impact\":\"This is a substantive business update. Its relevance depends on whether it changes revenue growth, margins, capacity, competitive positioning or execution visibility.\",\"importance_score\":4,\"completeness_score\":3}],\"recent_news\":[{\"summary\":\"a press release dated October 08, 2026, titled \\\"Lupin Receives U.S. FDA Approval for Phytonadione Injectable Emulsion, USP\\\".\",\"category\":\"Press Release\",\"date\":\"08-Oct-2026 21:00:15\",\"source\":\"NSE filing\",\"industry\":\"Pharmaceuticals\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/Lupin2_08102026205937_SELetterPressRelease.pdf\",\"headline\":\"Business update\",\"impact\":\"This is a substantive business update. Its relevance depends on whether it changes revenue growth, margins, capacity, competitive positioning or execution visibility.\",\"importance_score\":4,\"completeness_score\":3},{\"summary\":\"a press release dated October 06, 2026, titled \\\"Lupin Launches Formoflo-G\u00ae MDI, World s First Fixed-dose Triple Combination Drug for COPD Management\\\".\",\"category\":\"Press Release\",\"date\":\"06-Oct-2026 09:38:12\",\"source\":\"NSE filing\",\"industry\":\"Pharmaceuticals\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/Lupin2_06102026093541_SELetterpressrelease.pdf\",\"headline\":\"Business update\",\"impact\":\"This is a substantive business update. Its relevance depends on whether it changes revenue growth, margins, capacity, competitive positioning or execution visibility.\",\"importance_score\":4,\"completeness_score\":4},{\"summary\":\"a press release dated September 28, 2026, titled \\\"Lupin Receives Tentative Approval from U.S. FDA for Novel Apixaban Oral Suspension\\\".\",\"category\":\"Press Release\",\"date\":\"28-Sep-2026 09:13:36\",\"source\":\"NSE filing\",\"industry\":\"Pharmaceuticals\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/Lupin2_28092026091311_SELetterPressRelease.pdf\",\"headline\":\"Business update\",\"impact\":\"This is a substantive business update. Its relevance depends on whether it changes revenue growth, margins, capacity, competitive positioning or execution visibility.\",\"importance_score\":4,\"completeness_score\":3},{\"summary\":\"a press release dated September 04, 2026, titled \\\"Lupin Receives U.S. FDA Approval for Modafinil Tablets, USP\\\".\",\"category\":\"Press Release\",\"date\":\"04-Sep-2026 17:38:35\",\"source\":\"NSE filing\",\"industry\":\"Pharmaceuticals\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/Lupin2_04092026173742_SELetterPressRelease.pdf\",\"headline\":\"Business update\",\"impact\":\"This is a substantive business update. Its relevance depends on whether it changes revenue growth, margins, capacity, competitive positioning or execution visibility.\",\"importance_score\":4,\"completeness_score\":3}],\"shareholding_snapshot\":{\"promoter_pct\":46.84,\"public_pct\":53.16,\"fii_pct\":23.28,\"dii_pct\":23.78,\"mf_pct\":14.58,\"institutional_pct\":47.06,\"noninst_pct\":6.09,\"mf_scheme_count\":43,\"pledged_shares\":null,\"pledged_pct_of_promoter\":null,\"mf_holders\":[{\"name\":\"HDFC Mutual Fund-HDFC Arbitrage Fund\",\"shares\":21400375,\"pct\":4.68},{\"name\":\"Nippon Life India Trustee Ltd- A\/C Nippon India Growth Mid Cap Fund\",\"shares\":10673280,\"pct\":2.33},{\"name\":\"Mirae Asset BSE LARGEMID (60:40) Stable Dividend 50 ETF\",\"shares\":8586274,\"pct\":1.88},{\"name\":\"Sbi Arbitrage Fund\",\"shares\":5146361,\"pct\":1.13}],\"period\":\"30-SEP-2026\",\"submission_date\":\"19-OCT-2026\",\"source\":\"NSE shareholding pattern XBRL\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/xbrl\/SHP_1741171_19102026114146_WEB.xml\",\"previous_period\":\"30-JUN-2026\",\"previous_promoter_pct\":46.85,\"previous_fii_pct\":22.42,\"previous_dii_pct\":24.65,\"previous_mf_pct\":14.84,\"previous_institutional_pct\":47.07,\"previous_mf_scheme_count\":39,\"previous_pledged_pct_of_promoter\":null,\"previous_pledged_shares\":null},\"bulk_block_deals\":[{\"deal_type\":\"Block\",\"date\":\"2026-08-27T07:00:00+00:00\",\"party\":\"\",\"side\":\"Sell\",\"quantity\":\"\",\"price\":\"\",\"summary\":\"Price Action | Lupin shares slip as Citi downgrades to sell; ICICI Pru AMC slips 3% on block deal. Price Action | Lupin shares slip as Citi downgrades to sell; ICICI Pru AMC slips 3% on block deal Moneycontrol.com\",\"source\":\"Moneycontrol.com\"}]} --><\/p>\n","protected":false},"excerpt":{"rendered":"<p>LUPIN share price rose 1.61% to \u20b91,959.90 today. See why LUPIN is rising, volume context, company developments and what to watch next.<\/p>\n","protected":false},"author":1,"featured_media":8565,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"_witty_seo_title":"LUPIN Share Price Today: Why LUPIN Is Rising 1.61% | 26 October 2026","_witty_meta_description":"LUPIN share price rose 1.61% to \u20b91,959.90 today. See why LUPIN is rising, volume context, company developments and what to watch next.","_witty_primary_phrase":"LUPIN share price today","_witty_reason_label":"sectoral tailwinds and positive pharma momentum","_witty_reason_confidence":"medium","footnotes":"","_yoast_wpseo_title":"","_yoast_wpseo_metadesc":"","_yoast_wpseo_focuskw":"","rank_math_title":"","rank_math_description":"","rank_math_focus_keyword":"","_aioseop_title":"","_aioseop_description":""},"categories":[3,4],"tags":[222],"class_list":["post-8566","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-market-movers","category-stocks-in-news","tag-lupin"],"_links":{"self":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts\/8566","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/comments?post=8566"}],"version-history":[{"count":3,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts\/8566\/revisions"}],"predecessor-version":[{"id":8815,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts\/8566\/revisions\/8815"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/media\/8565"}],"wp:attachment":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/media?parent=8566"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/categories?post=8566"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/tags?post=8566"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}